Efficacy and Safety of Ipragliflozin (IPRA) in Japanese Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by Body Mass Index (BMI)

被引：0
|
作者：
Kashiwagi, Atsunori
Yoshida, Satoshi
Nakamura, Ichiro
Kazuta, Kenichi
Ueyama, Eiji
Takahashi, Hideyuki
Satomi, Hayato
Kosakai, Yoshinori
Kawamuki, Kousei
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1197-P
引用
收藏
页码：A309 / A309
页数：1
相关论文
共 50 条
  • [1] Gastric bypass for the treatment of type 2 diabetes mellitus (T2DM) in patients with body mass index (BMI) below 35
    Wilson, Camilo
    Escalona, Alex
    Munoz, Rodrigo
    Perez, Gustavo
    Crovari, Fernando
    Guzman, Sergio
    Ibanez, Luis
    OBESITY SURGERY, 2007, 17 (08) : 1041 - 1041
  • [2] Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials
    Kashiwagi, Atsunori
    Yoshida, Satoshi
    Nakamura, Ichiro
    Kazuta, Kenichi
    Ueyama, Eiji
    Takahashi, Hideyuki
    Satomi, Hayato
    Kosakai, Yoshinori
    Kawamuki, Kosei
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 544 - 554
  • [3] METABOLIC SURGERY FOR TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WITH BODY MASS INDEX (BMI) <30KG/M2: A METAANALYSIS
    Baskota, A.
    Li, S.
    Dhakal, N.
    Tian, H.
    OBESITY SURGERY, 2014, 24 (08) : 1211 - 1211
  • [4] Efficacy and Safety of Ertugliflozin in Hispanic/Latino Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)
    Liu, Jie
    Tarasenko, Lisa
    Ellison, Misoo C.
    Pong, Annpey
    Huyck, Susan
    Mancuso, James P.
    Terra, Steven G.
    Gantz, Ira
    DIABETES, 2019, 68
  • [5] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) and Concomitant Heart Failure
    Kosiborod, Mikhail
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Sugg, Jennifer E.
    Johnsson, Eva
    DIABETES, 2015, 64 : A313 - A313
  • [6] Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM)
    Liu, Jie
    Tarasenko, Lisa
    Pong, Annpey
    Huyck, Susan
    Wu, Larry
    Mancuso, James P.
    Terra, Steven
    Lauring, Brett
    DIABETES, 2018, 67
  • [7] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes (T2D): Outcomes by Body Mass Index (BMI)
    Shatskov, Alla
    Rezvani, Geoffrey
    Mansfield, Traci
    DIABETES, 2016, 65 : A299 - A299
  • [8] THE EFFICACY AND EFFECTIVENESS IN HBA1C-LOWERING IS DEPENDENT ON BASELINE BODY MASS INDEX (BMI) FOR SITAGLIPTIN BUT NOT CANAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM)
    Diels, J.
    Angermund, R.
    Schroeder, M.
    Worbes-Cerezo, M.
    Thompson, G.
    VALUE IN HEALTH, 2014, 17 (07) : A334 - A334
  • [9] EFFICACY AND SAFETY OF TREATMENTS OF TYPE 2 DIABETES MELLITUS (T2DM): A SYSTEMATIC REVIEW (SLR)
    Pettre, S.
    Selya-Hammer, C.
    Ho, S.
    Garg, M.
    Schroeder, M.
    Kaur, V
    Hemels, M.
    VALUE IN HEALTH, 2013, 16 (07) : A433 - A433
  • [10] Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study: BRIGHTEN: double-blind randomized study of ipragliflozin to show its efficacy as monotherapy in T2DM patients
    Kashiwagi A.
    Kazuta K.
    Takinami Y.
    Yoshida S.
    Utsuno A.
    Nagase I.
    Diabetology International, 2015, 6 (1) : 8 - 18
12345